Ubs Group Ag Renalytix PLC Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Renalytix PLC stock. As of the latest transaction made, Ubs Group Ag holds 279,743 shares of RNLX stock, worth $41,961. This represents 0.0% of its overall portfolio holdings.

Number of Shares

279,743

Previous 75 372890.67%

Holding current value

$41,961

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.21 - $0.45 $58,730 - $125,850	279,668 Added 372890.66%	279,743 $58,000
Q2 2024 Aug 13, 2024	BUY	$0.23 - $0.93 $17 - $69	75 New	75 $0
Q3 2023 Nov 09, 2023	SELL	$1.51 - $4.01 $3,546 - $9,419	-2,349 Reduced 36.65%	4,061 $6,000
Q2 2023 Aug 11, 2023	BUY	$2.0 - $2.92 $12,354 - $18,036	6,177 Added 2651.07%	6,410 $18,000
Q1 2023 May 12, 2023	SELL	$1.93 - $3.72 $14,913 - $28,744	-7,727 Reduced 97.07%	233 $0
Q4 2022 Feb 08, 2023	BUY	$1.06 - $2.21 $6,847 - $14,276	6,460 Added 430.67%	7,960 $14,000
Q3 2022 Nov 10, 2022	BUY	$1.19 - $2.78 $1,190 - $2,780	1,000 Added 200.0%	1,500 $2,000
Q2 2022 Aug 10, 2022	SELL	$2.45 - $7.81 $245 - $781	-100 Reduced 16.67%	500 $1,000
Q1 2022 May 16, 2022	SELL	$5.88 - $15.9 $14,952 - $40,433	-2,543 Reduced 80.91%	600 $4,000
Q4 2021 Feb 14, 2022	BUY	$13.43 - $27.4 $22,065 - $45,018	1,643 Added 109.53%	3,143 $50,000
Q3 2021 Nov 15, 2021	SELL	$17.91 - $34.78 $73,431 - $142,598	-4,100 Reduced 73.21%	1,500 $30,000
Q2 2021 Aug 13, 2021	BUY	$23.56 - $34.25 $84,816 - $123,300	3,600 Added 180.0%	5,600 $173,000
Q1 2021 May 12, 2021	BUY	$15.25 - $31.13 $20,450 - $41,745	1,341 Added 203.49%	2,000 $51,000
Q4 2020 Feb 11, 2021	BUY	$10.69 - $16.0 $7,044 - $10,544	659 New	659 $11,000

Others Institutions Holding RNLX

# of Institutions

Shares Held

3.91M

Call Options Held

13.7K

Put Options Held

View Full List

About Renalytix plc

Ticker RNLX
Exchange OTC
Sector Healthcare
Industry Health Information Services
Shares Outstandng 37,445,900
Market Cap $5.62M
Description
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data ...

More about RNLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account